RAPT Therapeutics, Inc. (RAPT) financial statements (2022 and earlier)

Company profile

Business Address 561 ECCLES AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:189,700111,50077,383
Cash and cash equivalents24,02724,91877,383
Short-term investments165,62786,592 
Other undisclosed cash, cash equivalents, and short-term investments46(10) 
Other undisclosed current assets3,2734,0983,123
Total current assets:192,973115,59880,506
Noncurrent Assets
Property, plant and equipment2,7412,9823,707
Other noncurrent assets2,922389389
Total noncurrent assets:5,6633,3714,096
TOTAL ASSETS:198,636118,96984,602
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,3257,3184,785
Accounts payable1,9992,3831,143
Accrued liabilities6,3264,9353,642
Deferred revenue1,0164,0964,000
Other liabilities254328471
Total current liabilities:9,59511,7429,256
Noncurrent Liabilities
Liabilities, other than long-term debt2,6613,0482,225
Deferred revenue511863 
Deferred rent credit2,1502,1852,225
Total noncurrent liabilities:2,6613,0482,225
Total liabilities:12,25614,79011,481
Stockholders' equity
Stockholders' equity attributable to parent186,380104,17973,121
Common stock322
Additional paid in capital470,629319,196235,049
Accumulated other comprehensive income (loss)(206)(177)20
Accumulated deficit(284,046)(214,842)(161,950)
Total stockholders' equity:186,380104,17973,121
TOTAL LIABILITIES AND EQUITY:198,636118,96984,602

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Revenues3,8135,042 
Gross profit:3,8135,042 
Operating expenses(73,022)(58,256)(43,629)
Operating loss:(69,209)(53,214)(43,629)
Nonoperating income51,3121,292
Investment income, nonoperating(1,270)(497) 
Foreign currency transaction gain (loss), before tax(258)249(24)
Loss from continuing operations before income taxes:(69,204)(51,902)(42,337)
Income tax expense (990)(660)
Net loss available to common stockholders, diluted:(69,204)(52,892)(42,997)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Net loss:(69,204)(52,892)(42,997)
Comprehensive loss:(69,204)(52,892)(42,997)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(29)(197)24
Comprehensive loss, net of tax, attributable to parent:(69,233)(53,089)(42,973)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: